Sundrug Q1 FY2027: Sales rise 3.7% but operating profit slips 1.5%
Revenue
¥215.3B
+3.7%
Full-year forecast
¥876.0B
Operating Profit
¥12.1B
-1.5%
Full-year forecast
¥48.8B
Net Income
¥8.0B
+0.9%
Full-year forecast
¥32.1B
Operating Margin
5.6%
Sundrug reported a 3.7% rise in revenue to ¥215,331 million for the fiscal first quarter ended June 2026, but operating profit slipped 1.5% to ¥12,091 million. Net income attributable to owners rose 0.9% to ¥8,017 million.
Earnings Highlights
Sundrug's revenue for the first quarter of fiscal 2027 rose 3.7% year on year to ¥215,331 million, but operating profit fell 1.5% to ¥12,091 million. Ordinary profit declined 2.2% to ¥11,880 million, while net income attributable to owners of the parent increased 0.9% to ¥8,017 million. Revenue was supported by solid pharmacy and e-commerce operations, renovation effects, and temporary demand for daily necessities, but unseasonable weather and softer inbound demand weighed on summer seasonal products. The operating margin narrowed to 5.6% from 5.9% a year earlier, a 0.3 percentage point decline. Net income still posted a modest increase, leaving the quarter with higher sales and net income but a small operating profit decline.
| Metric | FY2027 Q1 | FY2026 Q1 | Change |
|---|---|---|---|
| Revenue | ¥215,331 million | ¥207,698 million | +3.7% |
| Operating profit | ¥12,091 million | ¥12,276 million | -1.5% |
| Ordinary profit | ¥11,880 million | ¥12,147 million | -2.2% |
| Net income attributable to owners of parent | ¥8,017 million | ¥7,944 million | +0.9% |
Segment Performance
Drugstore business: segment revenue rose 2.9% to ¥137,114 million, but operating profit declined 3.1% to ¥6,627 million. Rain hurt summer seasonal products and inbound demand weakened, but pharmacy and e-commerce operations remained solid, store renovation effects helped, and temporary demand for daily necessities partly offset the shortfall. Labor cost control kept the operating margin above plan, though it still declined from a year earlier.
Discount store business: segment revenue increased 4.5% to ¥94,046 million, and operating profit grew 0.5% to ¥5,463 million. Steady sales of high-margin products such as confectionery lifted gross profit, while lower-than-assumed cashless settlement fees also supported earnings.
External sales mix: drugstore business 56.3%, discount store business 43.7%. Store count at quarter end: drugstore 1,157 (including 887 directly operated and subsidiaries), discount store 440, total 1,597.
| Segment | Revenue (incl. internal) | Change | Operating profit | Change |
|---|---|---|---|---|
| Drugstore business | ¥137,114 million | +2.9% | ¥6,627 million | -3.1% |
| Discount store business | ¥94,046 million | +4.5% | ¥5,463 million | +0.5% |
| Segment | Revenue | Share | Op. Profit | Op. Margin |
|---|---|---|---|---|
| Drugstore business | ¥121.3B | 56% | ¥6.6B | 5.5% |
| Discount store business | ¥94.0B | 44% | ¥5.5B | 5.8% |
Financial Position and Capital Policy
Total assets fell ¥10,218 million from the prior fiscal year-end to ¥465,286 million, mainly reflecting a decline in cash and deposits. Liabilities decreased ¥10,489 million to ¥179,014 million, due to lower accounts payable and income taxes payable. Net assets rose ¥270 million to ¥286,272 million, lifting the equity ratio to 61.5% from 60.1%, a 1.4 percentage point improvement.
For fiscal 2027, Sundrug plans an annual dividend of ¥132 per share (interim ¥66, year-end ¥66), up ¥1 from ¥131 in the previous fiscal year. No share buyback was announced this quarter. A cash flow statement was not prepared for the first quarter; depreciation totaled ¥4,656 million and goodwill amortization ¥28 million.
Risks and Challenges
The company's main recognized risks include:
- Intensifying competition for new drugstore and discount store locations
- Progress in industry consolidation among large operators
- Competition from other retail formats
- Fluctuations in energy prices and logistics costs
- Unseasonable weather and swings in inbound demand
In the first quarter, weather and weaker inbound demand dampened seasonal product sales in the drugstore business, contributing to lower operating profit. Management also continues to monitor persistent inflation, currency fluctuations, and geopolitical uncertainties including the Middle East situation.
Full-Year Outlook
Sundrug left its full-year earnings forecast unchanged from the guidance announced on May 15, 2026. The company projects revenue of ¥876,000 million (up 4.0%), operating profit of ¥48,800 million (up 4.2%), ordinary profit of ¥48,100 million (up 4.1%), and net income attributable to owners of the parent of ¥32,150 million (up 2.4%).
| Item | Previous forecast (May 15) | Current forecast | Prior-year actual (estimated) |
|---|---|---|---|
| Revenue | ¥876,000 million | ¥876,000 million | ¥842,308 million |
| Operating profit | ¥48,800 million | ¥48,800 million | ¥46,833 million |
| Ordinary profit | ¥48,100 million | ¥48,100 million | ¥46,206 million |
| Net income attributable to owners of parent | ¥32,150 million | ¥32,150 million | ¥31,396 million |
Analyst take
Sundrug's first quarter delivered solid revenue growth, but weaker profit in its core drugstore operations attracted attention. One-off factors like unseasonable weather and softer inbound demand, together with cost pressures from labor and store competition, likely squeezed margins. The discount store segment helped balance the portfolio by expanding profit on high-margin products. Maintaining the full-year forecast signals management's expectation of full-year sales and profit growth, making the pace of recovery in the drugstore segment a key focus. With an equity ratio of 61.5% and a planned dividend increase, shareholder returns are positive, but the medium-term question is how Sundrug will position for growth amid continuing industry realignment.